secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001558370-22-017836
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio Q3 2022 net loss $19.0M ($0.18/sh); cash $92.4M; MB-106 trial advances
--------------------------------------------------------------------------------

- Cash and equivalents $92.4M at Sep 30, 2022, down $16.0M from June 30, $110.6M at Dec 31, 2021.
- Net loss attributable to common stockholders $19.0M ($0.18/sh) vs $17.0M ($0.19/sh) in Q3 2021.
- First patient treated in Mustang-sponsored multicenter Phase 1/2 trial for MB-106 (CD20 CAR T) in B-NHL and CLL.
- Fred Hutch trial: 96% ORR, 75% CR in 28 patients; 12 patients CR >12 months; no Grade ≥3 CRS or ICANS.
- MB-106 granted FDA Orphan Drug Designation for Waldenstrom macroglobulinemia; early Phase 1 results expected Dec 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000155837022017836/0001558370-22-017836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000155837022017836/tmb-20221114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer